Molly Freeman on SBRT Aftercare for Patients with Lung Cancer

Serial CTRS, an AI-powered tool, has been granted FDA breakthrough device designation for classifying patients with NSCLC.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.

While the phase 2 trial did not meet its primary endpoint, it demonstrated that SBRT plus concurrent radiotherapy yielded better results than those observed in previous studies.